Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Selected Articles from This Issue

  • Selected Articles from This Issue
    Selected Articles from This Issue
    Mol Cancer Ther March 1 2020 19 (3) 729-729;

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas
    Long-Sheng Chang, Janet L. Oblinger, Sarah S. Burns, Jie Huang, Larry W. Anderson, Melinda G. Hollingshead, Rulong Shen, Li Pan, Garima Agarwal, Yulin Ren, Ryan D. Roberts, Barry R. O'Keefe, A. Douglas Kinghorn and Jerry M. Collins
    Mol Cancer Ther March 1 2020 19 (3) 731-741; DOI:10.1158/1535-7163.MCT-19-0809

  • Small Molecule Therapeutics
    Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling
    Sho Nakai, Hironari Tamiya, Yoshinori Imura, Takaaki Nakai, Naohiro Yasuda, Toru Wakamatsu, Takaaki Tanaka, Hidetatsu Outani, Satoshi Takenaka, Kenichiro Hamada, Akira Myoui, Nobuhito Araki, Takafumi Ueda, Hideki Yoshikawa and Norifumi Naka
    Mol Cancer Ther March 1 2020 19 (3) 742-754; DOI:10.1158/1535-7163.MCT-19-0358

  • Small Molecule Therapeutics | AuthorChoice
    Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression
    Shweta Joshi, Kevin X. Liu, Muamera Zulcic, Alok R. Singh, Dylan Skola, Christopher K. Glass, P. Dominick Sanders, Andrew B. Sharabi, Timothy V. Pham, Pablo Tamayo, Daniel Shiang, Huy Q. Dinh, Catherine C. Hedrick, Guillermo A. Morales, Joseph R. Garlich and Donald L. Durden
    Mol Cancer Ther March 1 2020 19 (3) 755-764; DOI:10.1158/1535-7163.MCT-19-0947

  • Small Molecule Therapeutics
    Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase
    Myung-Kyu Jang, Tetsuo Mashima and Hiroyuki Seimiya
    Mol Cancer Ther March 1 2020 19 (3) 765-776; DOI:10.1158/1535-7163.MCT-19-0668

  • Small Molecule Therapeutics
    Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck
    Gabrielle van Caloen, Sandra Schmitz, Mariama El Baroudi, Xavier Caignet, Sébastien Pyr dit Ruys, Pierre P. Roger, Didier Vertommen and Jean-Pascal Machiels
    Mol Cancer Ther March 1 2020 19 (3) 777-789; DOI:10.1158/1535-7163.MCT-19-0695

Large Molecule Therapeutics

  • Large Molecule Therapeutics | AuthorChoice
    Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
    Silvana T. Tivadar, Richard S. McIntosh, Jia Xin Chua, Robert Moss, Tina Parsons, Abed M. Zaitoun, Srinivasan Madhusudan, Lindy G. Durrant and Mireille Vankemmelbeke
    Mol Cancer Ther March 1 2020 19 (3) 790-801; DOI:10.1158/1535-7163.MCT-19-0221

  • Large Molecule Therapeutics | AuthorChoice
    Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
    Ting Sun, Wenjia Zhang, Yuan Li, Zhengyu Jin, Yang Du, Jie Tian and Huadan Xue
    Mol Cancer Ther March 1 2020 19 (3) 802-811; DOI:10.1158/1535-7163.MCT-19-0495

  • Large Molecule Therapeutics
    Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
    Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
    Mol Cancer Ther March 1 2020 19 (3) 812-821; DOI:10.1158/1535-7163.MCT-19-0890

  • Large Molecule Therapeutics
    Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
    Binbin Xie, Jianqin Wan, Xiaona Chen, Weidong Han and Hangxiang Wang
    Mol Cancer Ther March 1 2020 19 (3) 822-834; DOI:10.1158/1535-7163.MCT-19-0625

  • Large Molecule Therapeutics | AuthorChoice
    Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
    Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr and Daniel S. Pereira
    Mol Cancer Ther March 1 2020 19 (3) 835-846; DOI:10.1158/1535-7163.MCT-19-1079

Cancer Biology and Translational Studies

  • Cancer Biology and Translational Studies
    Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
    Melanie A. Krook, Alexandria Lenyo, Max Wilberding, Hannah Barker, Mikayla Dantuono, Kelly M. Bailey, Hui-Zi Chen, Julie W. Reeser, Michele R. Wing, Jharna Miya, Eric Samorodnitsky, Amy M. Smith, Thuy Dao, Dorrelyn M. Martin, Kristen K. Ciombor, John Hays, Aharon G. Freud and Sameek Roychowdhury
    Mol Cancer Ther March 1 2020 19 (3) 847-857; DOI:10.1158/1535-7163.MCT-19-0631

  • Cancer Biology and Translational Studies | AuthorChoice
    Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity
    Alexis V. Forterre, Jing-Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D. Pegram, Stefanie S. Jeffrey and A.C. Matin
    Mol Cancer Ther March 1 2020 19 (3) 858-867; DOI:10.1158/1535-7163.MCT-19-0928

  • Cancer Biology and Translational Studies
    Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
    Na Hao, Wenzhi Shen, Renle Du, Shan Jiang, Junyong Zhu, Yanan Chen, Chongbiao Huang, Yi Shi, Rong Xiang and Yunping Luo
    Mol Cancer Ther March 1 2020 19 (3) 868-881; DOI:10.1158/1535-7163.MCT-18-1233

  • Cancer Biology and Translational Studies
    Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
    Tomohiro Shibata, Kosuke Watari, Akihiko Kawahara, Tomoya Sudo, Satoshi Hattori, Yuichi Murakami, Hiroto Izumi, Junji Itou, Masakazu Toi, Jun Akiba, Yoshito Akagi, Maki Tanaka, Michihiko Kuwano and Mayumi Ono
    Mol Cancer Ther March 1 2020 19 (3) 882-894; DOI:10.1158/1535-7163.MCT-19-0690

  • Cancer Biology and Translational Studies
    Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
    Karine Flem-Karlsen, Erin McFadden, Nasrin Omar, Mads H. Haugen, Geir Frode Øy, Truls Ryder, Hans Petter Gullestad, Robert Hermann, Gunhild Mari Mælandsmo and Vivi Ann Flørenes
    Mol Cancer Ther March 1 2020 19 (3) 895-905; DOI:10.1158/1535-7163.MCT-19-0290

  • Cancer Biology and Translational Studies
    PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell–like Traits and Multiple Biomarkers
    Zhen-Zhen Zhang, Wei-Xing Yu, Min Zheng, Xin-Hua Liao, Ji-Chuang Wang, Da-Yun Yang, Wen-Xian Lu, Long Wang, Sheng Zhang, He-Kun Liu, Xiao Zhen Zhou and Kun Ping Lu
    Mol Cancer Ther March 1 2020 19 (3) 906-919; DOI:10.1158/1535-7163.MCT-19-0656

  • Cancer Biology and Translational Studies
    Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model
    Suzanne P. MacFarland, Koumudi Naraparaju, Radhika Iyer, Peng Guan, Venkatadri Kolla, Yuxuan Hu, Kai Tan and Garrett M. Brodeur
    Mol Cancer Ther March 1 2020 19 (3) 920-926; DOI:10.1158/1535-7163.MCT-18-1044

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
    Dina Cramer, Johanna Mazur, Octavio Espinosa, Matthias Schlesner, Daniel Hübschmann, Roland Eils and Eike Staub
    Mol Cancer Ther March 1 2020 19 (3) 927-936; DOI:10.1158/1535-7163.MCT-19-0045

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
    Changhee Park, Miso Kim, Min Jung Kim, Hyeongmin Kim, Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim and Dae Seog Heo
    Mol Cancer Ther March 1 2020 19 (3) 937-944; DOI:10.1158/1535-7163.MCT-19-0457

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer
    Waleed S. Al Amri, Lisa M. Allinson, Diana E. Baxter, Sandra M. Bell, Andrew M. Hanby, Stacey J. Jones, Abeer M. Shaaban, Lucy F. Stead, Eldo T. Verghese and Thomas A. Hughes
    Mol Cancer Ther March 1 2020 19 (3) 945-955; DOI:10.1158/1535-7163.MCT-19-0940

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer
    Song Ye, Xiaoge Hu, Chao Ni, Weiwei Jin, Yaping Xu, Lianpeng Chang, Huaixiang Zhou, Jiahong Jiang and Liu Yang
    Mol Cancer Ther March 1 2020 19 (3) 956-965; DOI:10.1158/1535-7163.MCT-18-1385

Models and Technologies

  • Models and Technologies | AuthorChoice
    Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease
    Myungeun Lee, Zhi Hong Lu, Jie Li, Elena A. Kashentseva, Igor P. Dmitriev, Samir A. Mendonca and David T. Curiel
    Mol Cancer Ther March 1 2020 19 (3) 966-971; DOI:10.1158/1535-7163.MCT-19-0768

Back to top
PreviousNext
Molecular Cancer Therapeutics: 19 (3)
March 2020
Volume 19, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas
  • Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression
  • Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
  • Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma

Jump to

  • Selected Articles from This Issue
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Translational Studies
  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
  • Models and Technologies
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement